1. Home
  2. PGZ vs SPRO Comparison

PGZ vs SPRO Comparison

Compare PGZ & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Principal Real Estate Income Fund of Beneficial Interest

PGZ

Principal Real Estate Income Fund of Beneficial Interest

HOLD

Current Price

$9.96

Market Cap

66.6M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

71.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGZ
SPRO
Founded
2012
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.6M
71.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PGZ
SPRO
Price
$9.96
$1.23
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.9K
708.3K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
12.26%
N/A
EPS Growth
N/A
111.81
EPS
N/A
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$9.32
$1.08
52 Week High
$10.64
$3.08

Technical Indicators

Market Signals
Indicator
PGZ
SPRO
Relative Strength Index (RSI) 31.95 38.90
Support Level $9.84 $1.10
Resistance Level $10.14 $1.29
Average True Range (ATR) 0.10 0.05
MACD -0.03 0.04
Stochastic Oscillator 3.74 56.80

Price Performance

Historical Comparison
PGZ
SPRO

About PGZ Principal Real Estate Income Fund of Beneficial Interest

Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Singapore, South Korea, British Virgin Islands and more.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: